Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which liver biopsy method wins? new study pits EUS against ultrasound

NCT ID NCT06047327

Diagnosis Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two methods of taking a liver tissue sample: one using an endoscope with ultrasound (EUS) and the other using a needle through the skin (percutaneous). Researchers wanted to see which method provides better samples for diagnosing liver disease. The trial involved 90 adults with liver cirrhosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the best biopsy method for accurate liver disease diagnosis.
What could go wrong
This is a small, completed study with 90 participants, so results may not apply to everyone. Both methods carry risks like pain or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients \> 18 years of age. 2. Eligibility for deep sedation with propofol. 3. Undergoing liver biopsy for diagnosis/evaluation/staging. Exclusion Criteria: 1. Coagulopathy, defined by platelet count \< 70,000/mL and/or INR \> 1.7. 2. Inability to discontinue anticoagulation or antiplatelet agents for 5 days prior to the procedure. 3. Presence of unrelieved biliary obstruction. 4. Presence of ascites. 5. Suspected or known hepatic malignancy. 6. Hypertensive patients with uncontrolled blood pressure. (SBP \>150 and/or DBP\>100mmHg) 7. Medically unfit for sedation. 8. Inability to provide informed consent. 9. Cannot understand Hindi or English should be excluded since they will not be able to reply objectively to questionnaire.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis

Contacts and locations

Locations

  • Institiute of liver and biliary sciences

    New Delhi, 110070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.